Loading
Reading the DNA (and sometimes RNA) of a tumour, usually with a panel of a few hundred genes, to list its mutations, fusions and amplifications and match them to approved drugs or trials. Guidelines now require it before first-line treatment in lung, colorectal, breast and prostate cancer, though in several cancer types most tumours still show no actionable finding.
Most clinical profiling uses a targeted panel of a few hundred cancer-relevant genes sequenced from a biopsy or from blood (liquid biopsy); comprehensive genomic profiling (CGP) reports mutations, amplifications, fusions, tumour mutational burden and microsatellite status in one assay. The result is matched to approved drugs, trials and resistance mechanisms, ideally in a molecular tumour board, and guidelines now require testing before first-line treatment in several cancers. Limits include tumours with no actionable finding (still the majority in many types), variants of uncertain significance, sampling one spot of a heterogeneous tumour, and unequal access.
Showing the technology this term belongs to: Comprehensive genomic profiling.
Shares FoundationOne CDx / Liquid CDx, Comprehensive genomic profiling and the tag precision.
Shares FoundationOne CDx / Liquid CDx and the tag precision.
Shares Whole-exome & whole-genome sequencing and the tag precision.
Shares Comprehensive genomic profiling and the tag precision.
Shares Liquid biopsy (ctDNA) and the tag precision.
Shares Liquid biopsy (ctDNA) and the tag precision.
Shares DNA, Biomarker, Biopsy, Liquid biopsy (ctDNA) and the tag precision.
Shares Next-generation sequencing (NGS), Liquid biopsy (ctDNA) and the tag precision.